First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (typical for pre-revenue biotech…
Watch on earnings: IMM-1-104 Phase 1/2 objective response rate (ORR) and progression-free survival (PFS) data in RAS-mutant solid tumors, Cash burn rate per quarter and updated cash runway projections (quarters of liquidity remaining), Clinical trial enrollment velocity and projected data readout dates for lead programs.
One Sentence Summary:
Immuneering: the story is balanced — imm-1-104 phase 1/2 clinical trial data releases (safety, efficacy signals in ras-mutant cancers).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.